for educational and safety purposes
Every compound in the sci-wiki that affects hair growth; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.
18 sourced · 5 reference
SM-04554 is a topical small molecule that activates Wnt/beta-catenin signaling, developed as a novel treatment for androgenetic alopecia. Rather than blocking androgens, it stimulates the pathway that governs the hair cycle, aiming to push follicle stem cells into the growth phase to regenerate follicles and maintain density. It advanced into late-stage clinical testing for pattern hair loss, making it one of the more prominent Wnt-based approaches to hair regrowth.
Topilutamide, better known as fluridil, is a topical antiandrogen purpose-built to fight hair loss at the scalp without the systemic side effects of oral treatments. It blocks the androgen receptor locally in hair follicles, then breaks down before it can enter the bloodstream, sparing libido and hormones. In a placebo-controlled study it meaningfully boosted the proportion of actively growing hairs, making it a compelling, targeted option for androgenetic alopecia.
RU-58841 is a potent non-steroidal topical antiandrogen developed for androgenetic alopecia, acne, and hirsutism. Applied directly to the scalp, it binds androgen receptors in the hair follicle and blocks dihydrotestosterone (DHT), the androgen that drives follicle miniaturization, while its rapid local metabolism limits hormonal effects elsewhere in the body. Decades of animal research show striking regression of androgen-dependent skin structures, making it one of the most studied local antiandrogens for hair loss.
Pyrilutamide (KX-826) is a next-generation topical androgen receptor antagonist developed for androgenetic alopecia, designed to block the hair-loss hormone DHT directly at the scalp while avoiding the systemic hormonal side effects of pills like finasteride [1][2]. Applied locally, it aims to shield hair follicles from androgen-driven miniaturization at the root cause of pattern hair loss [2][4]. One of the most closely watched investigational hair-loss drugs, it targets androgen signaling in the skin without lowering hormones throughout the body [1][2].
GHK-Cu + Methylene Blue Tallow Balm is a thoughtfully built topical that stacks three skin-loving actives in a single rub-on jar rather than a needle. The copper peptide GHK-Cu signals collagen and elastin renewal, low-dose methylene blue delivers standout antioxidant and mild antimicrobial support, and a nutrient-rich beef tallow base deeply hydrates while carrying the actives in. For anyone who wants repair, firmness, and antioxidant defense in one gentle, easy-to-use balm, this blend is a genuinely appealing pick.
JXL069 is an experimental mitochondrial pyruvate carrier (MPC) inhibitor developed in the University of California, Los Angeles hair-biology program as a novel metabolic approach to hair loss [1][2]. By blocking pyruvate's entry into mitochondria, it pushes hair follicle stem cells toward glycolysis and lactate production, the metabolic switch that wakes these dormant cells and drives a new hair growth cycle [2]. It is closely related to PP405, a topical clinical candidate from the same line of research now advancing through trials for pattern hair loss, although JXL069 itself is sold as a research chemical [3].
Antibalder is a topical hair-loss formulation concept rather than a single molecule, pairing the copper peptide GHK-Cu with the vasodilator minoxidil. The idea is to combine minoxidil, a well-established stimulator of hair follicles, with GHK-Cu, a copper-binding tripeptide used in skin and scalp care for its role in tissue repair. The evidence relates mainly to the two ingredients individually; there is little published data on this specific combination.
Biotin, also known as vitamin B7 (and historically as vitamin H), is a water-soluble B vitamin that the body needs as a coenzyme for several key metabolic enzymes. It acts as an essential cofactor for carboxylase enzymes involved in the metabolism of fats, carbohydrates, and amino acids [1]. True deficiency is rare because biotin is widespread in foods and is also made by gut bacteria, but it is a popular dietary supplement, most often marketed for hair, skin, and nail health despite limited supporting evidence in people who are not deficient [2]. High-dose biotin can also interfere with common laboratory blood tests [4].
KY-19382 is an experimental small molecule that activates the Wnt/beta-catenin signaling pathway, investigated as a treatment for hair loss. A synthetic analogue of the natural compound indirubin-3'-monoxime, it was developed by researchers at Yonsei University in South Korea, who reported that it promotes hair regrowth and the formation of new hair follicles in laboratory and animal models [1]. It is a preclinical research compound and is not an approved medicine [1].
Bicalutamide is a nonsteroidal antiandrogen, a drug that blocks the action of male sex hormones by competitively antagonizing the androgen receptor. It is used mainly in the treatment of prostate cancer, either combined with medical or surgical castration in advanced disease or, at a higher dose, as a single agent in earlier disease [1]. First approved in the mid-1990s under the brand name Casodex, it is taken as a once-daily oral tablet and is now available as a generic on the World Health Organization's List of Essential Medicines. Unlike some related drugs, it reduces androgen signaling without lowering the body's production of testosterone [1].
Eflornithine, also known as alpha-difluoromethylornithine (DFMO), is a medication that irreversibly inhibits the enzyme ornithine decarboxylase, a key step in the body's production of polyamines. It is used to treat West African sleeping sickness (the gambiense form of human African trypanosomiasis), to slow unwanted facial hair growth in a topical form, and more recently to reduce the risk of relapse in high-risk neuroblastoma.
Minoxidil + Aminexil is a combination approach to pattern hair loss that pairs minoxidil, a topical vasodilator and established hair-growth agent, with aminexil, a structurally related molecule developed by the cosmetics industry to counter the fibrosis that can loosen hair at the root. Minoxidil is the better-evidenced of the two, while aminexil (also called kopexil) appears mainly in cosmetic anti-hair-loss formulations. The pairing is used topically for androgenetic alopecia rather than being a single approved drug.
Minoxidil + Finasteride is a combination therapy widely used for male androgenetic alopecia that pairs two agents with complementary actions: minoxidil, a topical vasodilator that stimulates the hair follicle, and finasteride, a 5-alpha-reductase inhibitor that lowers levels of the androgen dihydrotestosterone (DHT). Together they address both the follicle and the hormonal driver of pattern hair loss, and clinical studies generally find the combination more effective than either drug alone. The two are used together as oral finasteride with topical minoxidil, or in combined topical formulations.
AHK (Tripeptide-3) is a copper-binding signal peptide, the alanine-histidine-lysine tripeptide prized in advanced hair and skin formulations. Its histidine and lysine residues grip copper to form the bioactive complex AHK-Cu, which has been shown to lengthen human hair follicles and energize the dermal papilla cells that drive hair growth. A close cousin of the celebrated copper peptide GHK, it is sought out as a next-level cosmetic peptide for hair density, skin renewal, and regeneration.
Finasteride is a medication that blocks the enzyme 5-alpha-reductase, lowering the body's production of the potent androgen dihydrotestosterone (DHT). It is used to treat enlarged prostate (benign prostatic hyperplasia) and male pattern hair loss, and is sold under the brand names Proscar and Propecia. By reducing DHT it shrinks the prostate and can slow or partly reverse androgen-driven hair loss.
CB-03-01, known as clascoterone, is a first-in-class topical androgen receptor inhibitor and the first genuinely new mechanism approved for acne in decades. Applied directly to the skin, it blocks androgen signaling in the sebaceous gland without the systemic hormonal effects of oral antiandrogens. For those seeking targeted, well-tolerated hormonal control of acne, clascoterone is a landmark advance.
Minoxidil is a vasodilator that opens ATP-sensitive potassium channels, originally developed and approved in 1979 as an oral treatment for severe high blood pressure. It is a prodrug: it is inactive until the sulfotransferase enzyme SULT1A1 in the hair follicle converts it to minoxidil sulfate, so a person's follicular enzyme activity helps predict whether they respond to it. Its tendency to promote hair growth, first noticed during blood-pressure trials, led to topical formulations approved for pattern hair loss and, more recently, to a resurgence of low-dose oral minoxidil, used off-label for hair loss with attention to fluid-retention and cardiovascular safety.
PP405 is an investigational topical small-molecule compound being developed for pattern hair loss, or androgenetic alopecia. It is designed to inhibit the mitochondrial pyruvate carrier, a strategy that grew out of research showing that blocking this carrier raises lactate inside hair follicle stem cells and reawakens dormant follicles. It remains experimental and has not been approved for medical use.
He Shou Wu, also known as fo-ti or tuber fleeceflower, is the processed root of Reynoutria multiflora (formerly Polygonum multiflorum), a climbing plant of the buckwheat family, Polygonaceae, native to China. It is one of the most widely used tonic herbs in traditional Chinese medicine, historically taken for hair color, vitality, and longevity. Modern attention has focused both on its bioactive stilbenes and anthraquinones and on well-documented cases of liver injury linked to its use.
Keraxidil is an experimental compound described as a tyrosinase-cleavable prodrug of minoxidil, a design intended to release the established hair-growth drug minoxidil selectively within active hair follicles. The concept combines minoxidil's known ability to stimulate hair growth with an enzyme-triggered delivery strategy meant to concentrate the drug at the follicle and limit exposure elsewhere [1][3]. It is an emerging, early-stage agent with little peer-reviewed data of its own, and it is not an approved medicine.
Saw palmetto is a lipidosterolic extract of the berries of Serenoa repens, a fan palm of the southeastern United States, and ranks among the most widely used herbal supplements for prostate health. Its proposed mechanism is genuinely pharmacological: in vitro the extract inhibits both isoenzymes of 5-alpha-reductase, the enzyme that converts testosterone to the more potent dihydrotestosterone, and interferes with androgen binding in prostate cells, alongside anti-inflammatory effects. Despite this rationale, rigorous placebo-controlled trials, including the NEJM STEP study and the dose-escalation CAMUS trial, and successive Cochrane reviews have generally found the standardized extract no more effective than placebo for lower urinary tract symptoms of benign prostatic hyperplasia. Evidence for certain proprietary hexanic preparations remains debated, and the extract is consistently well tolerated with minimal impact on sexual function.
Stinging nettle (Urtica dioica) is a herbaceous perennial plant in the family Urticaceae, well known for the stinging hairs on its leaves and stems. Long used as a food and in traditional medicine, its cooked young leaves are eaten as a nutritious green, while extracts of its root and leaf are taken as herbal remedies. The best-studied medicinal use is for the urinary symptoms of an enlarged prostate, though the overall evidence remains limited.
WAY-316606 is a research compound best known in the hair-loss world for switching on Wnt signaling, a growth pathway important for the hair follicle. It does this by blocking SFRP1, a natural brake on Wnt. In lab studies on human scalp follicles it encouraged hair growth, which is why it gets attention as a possible topical hair treatment. It is a research chemical, not an approved or marketed hair-loss drug.